Dyax CorpNASDAQ:DYAX

Help
Symbol Lookup
    No Matches were found for
    Additional matches for ...
     
    Go
    OverviewChartsNewsFundamentalsEarningsReportsCalendarOptionsTechnical Insight

    Symbol Lookup

    Close

    Search Criteria

    Name or Symbol

    Security Type

    Fund Categories

    Market

    Expiration Filter

    Chain Type

    Submit
    Saturday May 25, 2013 10:03 AM ET. Data delayed 15 minutes.
    2.61
    -0.01 (-0.38%)
    Price HistoryRefresh
    Bid/Lots
    2.61/71
    Ask/Lots
    2.62/465
    Open/Prev Close
    2.59/2.62
    Day Range
    2.50-2.63
    52-Week Range
    1.63-4.50
    Vol/Avg Daily Vol
    255.8K/678.2K

    TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

    Open a New Account, or Login if you're a client.

    DYAX Headlines

    Go
    view headlines only »

    May 23, 2013

    Dyax Corp. Announces Participation in Upcoming Investor Events
    8:00AM ET on Thursday May 23, 2013 by Business Wire
    Companies Mentioned: DB, DYAX

    Dyax Corp. (NASDAQ: DYAX) announced today its participation in the following investor events:

    -- Deutsche Bank 38th Annual db Access Health Care Conference on Wednesday, May 29 in Boston, Massachusetts. George Migausky, Executive Vice President and Chief Financial Officer, will speak at 4:10 p.m. ET.

    Dyax Corp. (NASDAQ: DYAX) announced today its participation in the following investor events:

    -- Deutsche Bank 38th Annual db Access Health Care Conference on Wednesday, May 29 in Boston, Massachusetts. Geo...

    May 16, 2013

    Dyax HAE Allies(SM) Awards Program Launches on Second Annual Hereditary Angioedema (HAE) Day - a Global Event to Raise Awareness of HAE
    8:30AM ET on Thursday May 16, 2013 by Business Wire
    Companies Mentioned: DYAX

    To mark the second annual Hereditary Angioedema (HAE) Day, Dyax Corp. today announced the launch of HAE Allies, a new program recognizing the physicians, nurses, family members and friends who support HAE patients in their efforts to live life to the fullest. By drawing from the inspiring stories of individual HAE patient allies nationwide, the program seeks to underscore the value of support for those living with this potentially life-threatening condition, which is characterized by spontaneous episodes of edema, or swelling, in the face, feet, hands, throat, and abdomen.

    To mark the second annual Hereditary Angioedema (HAE) Day, Dyax Corp. today announced the launch of HAE Allies, a new program recognizing the physicians, nurses, family members and friends who support HAE patients in their ...

    May 13, 2013

    Sector Update: Healthcare Shares Lower; Theravance up 13% on Royalty Pact with Elan
    8:43AM ET on Monday May 13, 2013 by Midnight Trader
    Companies Mentioned: GSK, PSTI, THRX, DYAX, ELN
    08:43 AM EDT, 05/13/2013 (MidnightTrader) -- Health care stocks: JNJ: +0.05% PFE: -0.07% ABT: flat MRK: -0.11% AMGN: -0.66% Healthcare shares are generally lower in pre-market trading, although Pluristem Therapeutic (PSTI) is up 3% at $3.06 a...
    08:43 AM EDT, 05/13/2013 (MidnightTrader) -- Health care stocks: JNJ: +0.05% PFE: -0.07% ABT: flat MRK: -0.11% AMGN: -0.66% Healthcare shares are generally lower in pre-market trading, although Pluristem Therapeutic (PSTI) is up 3% at $3.0...
    Sector Update: Healthcare
    8:32AM ET on Monday May 13, 2013 by Midnight Trader
    Companies Mentioned: GSK, PSTI, THRX, DYAX, ELN
    08:32 AM EDT, 05/13/2013 (MidnightTrader) -- Healthcare shares are generally lower in pre-market trading, although Pluristem Therapeutic (PSTI) is up 3% at $3.06 as it reports its PLacental eXpanded cells tested in preclinical animal models of preec...
    08:32 AM EDT, 05/13/2013 (MidnightTrader) -- Healthcare shares are generally lower in pre-market trading, although Pluristem Therapeutic (PSTI) is up 3% at $3.06 as it reports its PLacental eXpanded cells tested in preclinical animal models of pr...
    Dyax Prices $30 Mln Direct Offering
    7:20AM ET on Monday May 13, 2013 by Midnight Trader
    Companies Mentioned: DYAX
    07:20 AM EDT, 05/13/2013 (MidnightTrader) -- Dyax (DYAX) said it priced a registered direct offering with RA Capital Management, Venrock, Federated Investors, Inc. and one other institutional investor for gross proceeds of approximately $30 million....
    07:20 AM EDT, 05/13/2013 (MidnightTrader) -- Dyax (DYAX) said it priced a registered direct offering with RA Capital Management, Venrock, Federated Investors, Inc. and one other institutional investor for gross proceeds of approximately $30 milli...
    ← Newer12Older →

    Peers Headlines

    May 23, 2013

    Repligen CEO to Present at Jefferies 2013 Global Healthcare Conference
    1:39PM ET on Thursday May 23, 2013 by GlobeNewswire
    Companies Mentioned: RGEN

    Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 4:30 p.m. ED...

    May 13, 2013

    Semi-Annual Changes to the NASDAQ Biotechnology Index
    8:00AM ET on Monday May 13, 2013 by GlobeNewswire
    Companies Mentioned: NDAQ, PGNX, RGEN, FURX, ANAC, ACAD, NLNK, CLVS, AMRI, HPTX, SCMP, SGYP

    The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, May 20, 2013.

    May 8, 2013

    Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments
    4:00PM ET on Wednesday May 08, 2013 by GlobeNewswire
    Companies Mentioned: IMMU

    Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial resul...

    May 7, 2013

    Immunomedics Announces Three New Patent Awards
    8:30AM ET on Tuesday May 07, 2013 by GlobeNewswire
    Companies Mentioned: IMMU

    Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it has re...

    Targacept Posts Narrower Q1 Loss Vs. Street, Beats on Revenues
    7:52AM ET on Tuesday May 07, 2013 by Midnight Trader
    Companies Mentioned: TRGT
    07:52 AM EDT, 05/07/2013 (MidnightTrader) -- Targacept (TRGT) reported a Q1 loss of $0.24 per share, versus the Capital IQ consensus of $0.33 loss per share. In the same period last year, the company posted EPS of $0.07. Revenues were $3.5 millio...
    Targacept Reports First Quarter 2013 Financial Results
    7:35AM ET on Tuesday May 07, 2013 by Business Wire
    Companies Mentioned: TRGT

    Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today reported its financial results for the first quarter ended March 31, 2013.

    May 2, 2013

    Repligen Reports First Quarter 2013 Financial Results
    7:33AM ET on Thursday May 02, 2013 by GlobeNewswire
    Companies Mentioned: RGEN

    - Total Revenue and Bioprocessing Revenue Grow 28% Over First Quarter 2012 -

    - Net Income Increases 91% to $2.3 million -

    - Earnings Conference Call and Webcast Today at 9:00 a.m. EDT -

    Repligen Corporation (Nasdaq:RGEN) to...

    Apr 30, 2013

    Targacept to Report First Quarter 2013 Financial Results on May 7, 2013
    8:55AM ET on Tuesday Apr 30, 2013 by Business Wire
    Companies Mentioned: TRGT

    Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it will report financial results for the first quarter of 2013 on the morning of Tuesday,...

    Apr 29, 2013

    Targacept Climbs 2% on Completed Patient Enrollment for Alzheimer's Study
    2:20PM ET on Monday Apr 29, 2013 by Midnight Trader
    Companies Mentioned: TRGT
    02:20 PM EDT, 04/29/2013 (MidnightTrader) -- Targacept Inc. (TRGT) is up 1.6% to $4.51 after reporting that it has completed recruitment of patients in the phase 2b study of TC-1734 as a treatment for mild to moderate Alzheimer's disease. The co...
    Targacept Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer's Disease
    8:55AM ET on Monday Apr 29, 2013 by Business Wire
    Companies Mentioned: TRGT

    Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has completed recruitment of patients in the Phase 2b study of TC-1734 as a treatment...

    ← Newer12Older →

    K=Thousands, M=Millions, B=Billions, TTM=Trailing 12 Month, MRQ=Most Recent Quarter, FYR=Fiscal Year End, NM=Not Meaningful, NA=Not Available

    GAAP = Generally Accepted Accounting Principles used in Financial Statements issued by the company, Non-GAAP = Adjusted Operating Earnings or Revenue used in comparison to Analyst Estimates. Adjustments are typically one-time gains or losses

    10:03 AM May 25, 2013
    Copyright ©2013 TD Waterhouse Canada Inc. All rights reserved.
    Privacy Policy | Internet Security | Legal
    Quotes, News, and Fundamentals provided by
    View restrictions
    News provided by